Angiotensin II (AII) plays a critical role in cardiac remodeling. This peptide promotes cardiac myocyte hypertrophy and cardiac fibroblast interstitial fibrotic changes associated with left ventricular hypertrophy, post myocardial infarction remodeling and congestive heart failure. AII mediates cardiac myocyte hypertrophy directly via induction of immediate early genes through a MAP kinase dependent pathway. In addition, it mediates cardiac hypertrophy indirectly by stimulating release of norepinephrine from cardiac nerve endings and endothelin from endothelial cells. AII also has multiple effects on cardiac fibroblasts: it induces cardiac fibroblast proliferation, synthesis and secretion of adhesion molecules and extracellular matrix proteins, and expression of integrin adhesion receptors. In addition it stimulates cardiac fibroblasts to adhere more vigorously to defined matrixes. This review will discuss the molecular pathways that have been implicated in these AII induced effects in the cardiac fibroblast.
AII and cardiac fibrosis
either an ACEI or with an AII subtype I (AT1) receptor blocker; mortality was decreased for the AT1 receptor The improvement in outcomes for patients with myocarblocker [7] . In a subsequent trial, ELITE II, AT1 receptor dial infarction and heart failure treated with angiotensin blockade and ACEI were associated with similar mortality. converting enzyme inhibitors (ACEI) compared to placebo Thus, the majority of the benefit imparted by ACE have been well demonstrated [1] [2] [3] [4] . However, the specific inhibitors appears to result from blocking untoward effects mechanisms by which ACEI exert their protective actions of angiotensin II mediated by the AT1 receptor. are not known. Although it was initially hypothesized that Based on these observations, ongoing studies of the they are beneficial due to their hemodynamic effects to effects of AII on the cardiovascular system are being reduce afterload, it is now known that their efficacy is not vigorously pursued. The heart expresses several compocompletely accounted for on this basis. In the V-HeFT II nents of the renin-angiotensin system, and AII has multistudy, enalapril was shown to be more effective in ple effects on both the cardiomyocytes and cardiac fipreventing progression of heart failure than treatment with broblasts [8, 9] . AII promotes cardiomyocyte hypertrophy, hydralazine plus isosorbide dinitrate despite similar blood cardiac fibroblast hyperplasia, and interstitial cardiac fipressure responses [5] . Thus, direct tissue effects have brosis [8] [9] [10] [11] [12] [13] [14] . These latter two actions, which increase the been implicated. ACE is responsible for catalyzing the volume of the non-myocyte compartment of the heart, are degradation of kinins as well as the conversion of anpredicted to have a particularly negative impact to promote giotensin I (AI) to angiotensin II (AII) [6] . Both actions the progression of LVH and the globular heart formation have been implicated in the cardiac protective effects of associated with post MI remodeling and HF (for review, ACEI. However, the ELITE trial compared outcomes of see Ref.
[8]). Firstly, interstitial fibrosis contributes to patients over age 65 with heart failure (HF) treated with ventricular wall stiffness and consequently impairs cardiac compliance, contributing to impaired diastolic function *Corresponding author. Tel.: 11-310-794-7555; fax: 11-310-794-7654.
Time for primary review 23 days. [15, 16] . Secondly, since neither the ECM nor the fiexpression in cardiac fibroblasts, and the functional impact broblasts contribute to systolic contraction, increased ECM of modulation of integrin expression both in vitro and in and fibroblast volume means that systolic work is being vivo. performed by a smaller proportion of the cardiac mass,
Integrins are a ubiquitous family of transmembrane contributing to systolic dysfunction. Thirdly, interstitial receptors, which interact with and induce responses of the fibrosis leads to increased distance that oxygen must cell to its external environment (Fig. 1 ). They mediate a diffuse and therefore potentially lowers PaO for the number of cellular functions including adhesion, migration, 2 working myocytes [17] . Finally, electrical coupling of the growth and apoptosis (for reviews, see Refs. [18] [19] [20] [21] ). cardiomyocytes may be impaired by the accumulation of Integrins are heterodimers composed of a and b subunits, ECM proteins and fibroblasts since such accumulation of which there are many isoforms, accounting for the first causes morphologic separation of myocytes [9] . Thus, of several levels of diversity imparted by these proteins. changes in the interstitium profoundly affect myocyte
The large extracellular portion of integrins binds directly to metabolism and performance, and ultimately, ventricular ECM proteins. Specific integrin heterodimers bind to function. Therefore, factors that contribute to cardiac specific yet overlapping subsets of integrin ligands. b1 interstitial fibrosis should be recognized, and investigations containing integrins are known to bind collagen, the avb5 should address whether approaches that attenuate fibrosis integrin to bind vitronectin, and the avb3 integrin to bind a improve ventricular function and remodeling.
variety of ECM proteins containing the peptide sequence arginine-glycine-aspartate (RGD sequence) including collagen, vitronectin, fibronectin, thrombin, fibrinogen and 2. Integrins: mediators of adhesion thrombospondin. The relatively short integrin cytoplasmic tail binds to various adapter proteins. The adapter proteins While the exact mechanisms by which AII induces in turn interact with transmembrane growth factor recardiac fibrosis is not known, recent work supports a ceptors, cytoplasmic kinases, and cytoskeletal proteins. critical role for adhesion, a complex process involving Integrins, thereby, mediate changes in cell shape and signal interactions between different families of factors, including transduction, which impact on nearly all critical cell integrins, ECM proteins, and adhesion molecules. An functions. important relevant issue is the regulation of integrin When integrins bind to ECM ligands, they cluster within ation via associations with growth factor receptors, which also accumulate in focal adhesions; some growth factor receptors may require such interaction for full activation AII attenuated cell adhesion to its extracellular matrix [22] [23] [24] [25] [26] [27] . Additionally, integrin interactions can impact milieu (for summary of above results, see Table 1 ). expression of multiple components of cell cycle control, AII has similar but somewhat different actions on e.g. cyclin D1 and the cyclin dependent kinase (cdk) human cardiac fibroblasts, although the overall profibrotic inhibitors p21 and p27 [28, 29] . Finally, ECM-integrin impact of AII appears to be conserved across species. In interactions may result in signal transduction events which fibroblasts obtained from explanted human carultimately effect transcriptional regulation of ECM prodiomyopathic hearts, we found an inverse relationship teins, as well as integrins, themselves [21, 30, 31] .
between the mRNA levels of atrial natriuretic peptide (ANP) vs. AT1 receptor, suggesting progressive down regulation of the AT1 receptor with increasing heart failure 2.1. Angiotensin II and integrin mediated adhesion [33] . However, northern and FACS analysis demonstrated no acute down regulation of AT1 receptor by AII treatment To determine if RGD binding integrins might play a role of the human cardiac fibroblasts in culture, in contrast to in AII induced cardiac interstitial fibrosis, we investigated the downregulation seen with rat cardiac fibroblasts. the expression pattern of av, b1, b3, and b5 integrins that Similar to findings in rodent cardiac fibroblasts [10] , AII we detected in cardiac fibroblasts [32] . These integrins induced c-fos and EGR-1 mRNA, as well as MAPK were found via fluorescence activated cell sorting (FACS) activity and a marked increase (53) in DNA synthesis. analysis to be present on the surface of both rat and human Treatment with the MAPK inhibitor PD98059 blocked this cardiac fibroblasts. AII up-regulated av, b1, b3, and b5 increase in DNA synthesis. AII also stimulated an increase integrin message and protein, which was blocked by the (23) in the expression of the pro-fibrotic factor TGF-b, AT1 receptor blocker irbesartan, but not by the AT2 the ECM proteins laminin and fibronectin, and the inhibreceptor blocker PD 123319. We tested the functional itor of protease activation, plasminogen activator inhibitorsignificance of the induction of expression of these genes 1 (PAI-1). AII also increased attachment of cells to by determining the ability of cardiac fibroblasts to adhere collagen I and III, the dominant ECM proteins of the to several ECM integrin ligands. AII promoted attachment human heart; this attachment was associated with an of rat cardiac fibroblasts to the ECM proteins collagen I, increase in focal adhesion kinase (FAK) activity, supportfibronectin, vitronectin, and laminin, and AII treatment ing a role for integrins in this effect. Each of these effects was associated with increased activation of FAK when were blocked by irbesartan but not by an AT2 receptor fibroblasts were allowed to adhere to these ECM proteins.
blocker. However, unlike our findings in rodent cardiac Pre-treatment with AT1 receptor blockers, irbesartan or fibroblasts, AII did not increase attachment to fibronectin, losartan, inhibited AII enhancement of cardiac fibroblast vitronectin or laminin or enhance integrin expression in adhesion to these substrates. Significantly, pretreatment human cardiac fibroblasts. with anti-b3 integrin antibody also attenuated the induction of adhesion to all four of these substrates by AII, while antibody directed at avb5 attenuated the increased adhe-3. Osteopontin: a novel adhesion protein in the heart sion only to vitronectin, its putative ligand. These results indicate that b3 integrin plays a significant role in AII Osteopontin (OPN) is an adhesion protein implicated as induced adhesion to all four of these substrates, while the one important mediator of the profibrotic effects of AII in avb5 role is limited to vitronectin. Thus, blocking the the heart. It was initially identified in bone, but is now increased integrin expression or integrin ligand binding by known to be synthesized in many tissues [34] . It has been proposed to bind calcium as well as fibronectin and collagen. Additionally, it contains an RGD sequence recognized by several integrins. Recent studies have demonstrated that it binds to avb1, avb3, and avb5 integrins and in vascular smooth muscle cells is acutely upregulated by cytokines and growth factors such as transforming growth factor b (TGFb), epidermal growth factor (EGF), platelet derived growth factor (PDGF), and interleukin 2 (IL-2), supporting a role for it as a mediator of cellular responses [35] [36] [37] [38] . In fact, OPN is recognized to contribute to vascular smooth muscle cell (VSMC) migration, adhesion, and spreading, and has been cloned as a gene differentially expressed in VSMC following arterial injury [39, 40] . OPN has also been shown to play a critical We demonstrated that OPN is expressed in the myocardium, in both myocytes and fibroblasts ( [42, 43] ; for review, see Ref. [44] ). Its ventricular expression positively Antibodies against OPN or b3 integrin block the prolifer-
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correlates with ventricular hypertrophy, and AII (10 M) ative effect of AII on cardiac fibroblasts in vitro, demonupregulates expression of OPN message several-fold withstrating that this effect is mediated via an OPN and in 6-24 h in cardiac fibroblasts. Monoclonal antibody integrin b3 dependent pathway. Studies are presently directed against OPN completely blocks the mitogenic underway to determine the exact role of OPN in the effect of AII on cultured rat cardiac fibroblasts, and development of cardiac fibrosis. partially blocks AII induction of cardiac fibroblast collagen gel contraction, a model of fibroblast scar contraction behavior. These findings suggest OPN may be an imReferences portant mediator of AII induced cardiac remodeling. In addition, anti-integrin (b3) antibody also blocked these pathway.
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